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Abstract 
Iron oxide nanoparticles with engineered physical and biochemical properties are finding a 
rapidly increasing number of biomedical applications. However, a wide variety of safety 
concerns, especially those related to oral exposure, still needs to be addressed in order to 
reach the clinical practice. Here, we report on the effects of chronic oral exposure to low dose 
of γ-Fe2O3 nanoparticles in growing chickens. Animal observation, weight and diet intake 
reveal no adverse signs, symptoms, or mortality. No nanoparticle accumulation was observed 
in liver, spleen and duodenum, while faeces are the main excretion route. Liver iron level and 
duodenal villi morphology reflect the bioavailability of the iron released from the partial 
transformation of γ-Fe2O3 nanoparticles in acid gastric environment. Duodenal gene 
expression studies related to the absorption of iron from γ-Fe2O3 nanoparticles indicate the 
enhancement of ferric over ferrous pathway supporting the role of mucins. Our findings 
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reveal that oral administration of iron oxide nanoparticles is a safe route for drug delivery at 
low nanoparticle doses. 
 
1. Introduction 
Progress in nanotechnology has brought countless novel applications[1] in different 
areas such as material science, energy or health. In the latest, nanometre-scale chemical 
engineering is providing novel tools for diagnostics, therapeutics and sensoring[2-3].  
One example is given by iron oxide nanoparticles (IONP), which are finding a rapidly 
increasing number of biomedical applications thanks to their suitable structural, 
colloidal, and magnetic properties[4]. Nowadays, IONP are employed as suitable 
platforms for biosensing[2], biomolecular-magnetic trapping[5], magnetic 
hyperthermia[6], imaging[7], drug- or gene-delivery[8-9]. There is a wide variety of 
IONP preparation methods providing controllable nanoparticle size and customized 
physical, chemical and biological functionalities without cytotoxicity drawbacks[4, 10-
14]. The coprecipitation of iron salts in water is the most widely used chemical method 
for synthesis of IONP[14]. Such chemical route provides crystalline IONP from the 
transformation of a mixture of ferric and ferrous salts in alkaline aqueous medium. 
Appropriated chemical procedures[4, 15] allow to prepare single-phase IONP avoiding 
the coexistence of Fe3O4 and γ-Fe2O3 phases and therefore different iron oxidation 
states (i.e. Fe(II) and Fe(III)) present into the same nanoparticle. 
The success of IONP on distinct biomedical applications requires to overcome safety 
concerns[16-18]. The assessment of IONP toxicity, biodistribution and excretion routes 
after long-term exposure is mandatory prior to a safe incorporation into clinical 
practice. Little attention has been paid to the effects related to IONP oral exposure in 
spite of the use of engineered nanoparticles for nutritional[19-23] and pharmaceutical 
[8, 24-25] purposes is expected to increase[20, 26-27]. An important issue is related to 
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the oral administration of nanoparticles where magnetic ones offer the possibility to 
magnetically guide the drug delivery to intentionally enhance the drug release into the 
affected tissue[8]. There exist toxicity and gastro-intestinal functioning concerns 
related to the oral exposure to IONP, especially regarding the absorption of metals like 
iron[20, 28-29].  Dietary iron is found in two basic forms[30-31], either as haem –
found in meat- or non-haem iron -present in cereals, vegetables, beans, fruits, etc. in a 
number of forms ranging from simple iron oxides and salts to more complex organic 
chelates. Haem iron is more bioavailable than the non-haem form and their absorption 
takes place by different pathways. It is well accepted that the main iron absorption 
takes place in duodenum. In case of non-haem iron, there are two main transport 
mechanisms to enter into enterocytes. These mechanisms tightly depend on the iron 
oxidation state: ferrous (i.e. Fe(II)), or ferric (i.e. Fe(III)) forms. Thus, luminal Fe(II) 
absorption involves divalent metal transporter-1 (DMT1) whereas luminal Fe(III) is 
proposed to undergo enzymatic reduction to Fe(II), by duodenal cytochrome B 
(DcytB), prior to apical DMT1 transport from lumen into labile iron pool in the 
cytoplasm of the enterocytes. Recently, Simovich et al. [32] proposed a novel and 
different ferric pathway at the apical surface of the villus which is specific for the 
uptake of the ferric form without previous enzymatic reduction. Such iron transport 
process involves the participation of four proteins in two stages. Firstly, luminal Fe(III) 
is chelated by mucins, then ferrous iron crosses the membrane in association with β3-
integrin and mobilferrin to internalize into cytosol. Secondly, this Fe(III) and protein 
complex combines with flavin monooxygenase and β2-microglobulin (β2-m) leading to 
paraferritin complex where Fe(III) is reduced to Fe(II). Once non-haem iron is inside 
the enterocyte, it can be either stored as ferritin or exported through the basolateral 
membrane from the ferrous iron pool to blood stream by the combined action of 
ferroportin (FPN) and hephaestin.[30] 
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The effects of nanomaterials on intestinal functioning have recently started to be 
evaluated. Some works on iron containg nanoparticles[20, 23, 33] show that iron from 
nanoparticles is bioavailable allowing to nanoparticles to act as efficient iron sources 
spite of the fact the duodenal absorption pathways remain still unknown.[21, 34-35] 
For this purpose, broiler chicken has been shown to be a suitable and accurate animal 
model for iron absorption and bioavailability studies[28, 36]. The broiler chickens are 
useful model for initial screening of Fe bioavailability in foods due to its growth rate, 
anatomy, size, and low cost. Recent results indicate that this animal model exhibits the 
appropriate responses to Fe deficiency and has potential to serve as a model for Fe 
bioavailability[36].  Previous studies related to oral exposure to IONP in mice reveal 
the genotoxic effects after acute and prolonged oral exposure[16, 25, 37-38]. The 
controversial variety of results underlines the need to clarify the influence of IONP oral 
exposure on the intestinal functioning for the sake of safety issues in oral biomedical 
applications[7-8].  
Here, we report on the effects of chronic oral exposure to IONP in growing chickens. 
Animal observation, diet intake and body weight reveal no adverse signs, symptoms, or 
mortality after 14 days of low dose IONP oral exposure. No IONP accumulation in 
liver, spleen and duodenum has been observed, while faeces appear as the main IONP 
excretion route. In addition, the liver iron level and the duodenal villi morphology 
reveal that iron from IONP is available. The analysis of haematological parameters 
indicates normality after chronic IONP dietary treatment. Duodenal gene expression 
studies on non-haem iron transport indicate that the ferrous pathway is inhibited whilst 
the ferric pathway is enhanced, supporting the involvement of mucins in iron solubility 
and transport into enterocytes. 
 
2. Materials and methods 
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2.1 Synthesis of γ-Fe2O3 nanoparticles 
The synthesis of γ-Fe2O3 nanoparticles coated with amino dextran (AD) was carried 
out in two steps procedure. In the first step, Fe3O4 nanoparticles were synthesized 
following the co-precipitation protocol described by Massart et al.[14]  and including 
some modification[39] of the reaction conditions allows to obtain γ-Fe2O3 IONP of 12 
nm size and narrow size distribution. In the second step, we proceed to modify the 
surface of nanoparticles. An aqueous solution of 500 mg of nanoparticles was 
dispersed in 70 mL of water at pH 11 (adjusted with KOH). AD (500 mg) was 
dissolved in 30 mL of water and added to nanoparticle dispersion very slowly and 
sonicated for twelve hours. The excess of coating was washed by dialysis against 
distilled water. Finally, the particles were dried on a stove to get the γ-Fe2O3 IONP 
powder. 
2.2 Structural characterization of γ-Fe2O3 nanoparticles 
Particle shape, size and size distribution were determined by Transmission Electron 
Microscopy (TEM) using the 200 KeV JEOL 2000 FXII microscope for routine TEM 
images and 200 KeV JEOL JEM 2100 for high resolution Transmission Electron 
Microscopy (HRTEM) images. For that purpose nanoparticles were prepared by 
placing a drop of a dilute nanoparticle suspension on a carbon-coated copper grid 
covered with a perforated carbon film and allowing the solvent to evaporate slowly at 
room temperature. The nanoparticle size is 12 ± 2 nm. The average particle size and 
distribution were evaluated by measuring the largest internal dimension of 350 
particles for the sake of statistical validity. The different size populations are organized 
into a histogram and are adjusted to a log-normal function. The particle surface coating 
was characterized by Fourier transform infrared spectra, recorded between 4000 and 
300 cm-1 in a Bruker IFS 66 V-S spectrometer. Samples were prepared for infrared 
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characterization by diluting the iron oxide nanoparticle powder in KBr at 2% by weight 
and compressing the mixture, pressing it into a pellet. On the other hand, quantification 
of the coating was carried out by simultaneous thermogravimetric analysis and 
differential thermal analysis performed on a Seiko TG/DTA 320U thermobalance by 
heating particle dispersion from room temperature to 900 °C at 10 °C/ min under an air 
flow of 100 ml/ min.  
2.3 Magnetic characterization of iron oxide nanoparticles 
Magnetization cycles of IONP powder were carried out in a vibrating sample 
magnetometer 7410 Lakeshore up to 2 T. A mass of 4.6 mgFe of AD coated IONP 
powder was introduced into a sample holder for tracing magnetization loops at room 
temperature while sweeping the magnetic field at 0.25 T/min. Magnetization values are 
normalized to the γ-Fe2O3 mass. In addition, temperature dependence of alternating 
current (AC) magnetic susceptibility measurements were performed on IONP and 
mashed freeze-dried liver, spleen and faeces. Samples were transferred into gelatine 
capsules for AC magnetic susceptibility characterization using a QuantumDesign 
MPMS-XL SQUID magnetometer. The variation of the AC magnetic susceptibility 
was recorded under given AC field conditions (11 Hz and 0.41 mT) in a temperature 
range from 2 to 300 K. 
2.4 Diet formulations 
Three experimental diets were designed for the experiment. Diet A: basal corn-soybean 
diet; diet B: basal diet supplemented with ferrous sulphate (FeSO4); diet C: basal diet 
supplemented with powder of AD coated γ-Fe2O3 IONP. Diets in mash form and water 
were provided ad libitum to birds. All diets were formulated to meet or exceed the 
minimum requirements established by Spanish Foundation for the Animal Nutrition 
Development (FEDNA) for broiler chickens[40], except for iron in case of diet A.  
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2.5 Animal model 
A total of 60 one-day-old male broiler chicks (Cobb strain) were housed in electrically 
heated starter batteries in an environmentally controlled room. From 1
st
 till 7
th
 day, 
birds were fed ad libitum on diet B with an adaptation period. At the 7
th
 day, 36 birds 
were selected by similar weight (189 ± 3g) and haemoglobin level. At 8
th
 day, the 36 
selected chickens were divided in three groups for receiving different diets during 14 
days of dietary treatment period. Each dietary group was allocated in 3 cages (3 
replicates with 4 chicks per replicate). At the end of the dietary treatment period (21
st
 
day) birds were subjected to 8 hours fasting, and feed consumption per cage was 
recorded. Then, birds were individually weighted and prepared for blood sample 
extraction. After blood collection, all chicks were euthanized using carbon dioxide 
prior to the extraction of duodenal, liver and spleen samples. Experimental procedures 
were approved by Animal Care and Ethics Committee of Universidad Complutense de 
Madrid in compliance with the Ministry of Agriculture, Fishery and Food for the Care 
and Use of Animals for Scientific Purposes.  
2.6 Collection of Samples 
Faeces: At the 19
th
 day, clean stainless steel collection trays were placed under each 
cage, for collecting bird excreta during next 48 h (3 replicate per diet, 4 birds per 
replicate). A subsample of excreta per cage was collected in polyethylene bags and 
freeze-dried for subsequent determination of iron content. For AC magnetic 
susceptibility measurements, a pooled sample per diet was prepared out of 3 replicates 
with 4 birds per replicate. Blood samples: 7 birds per diet were randomly selected for 
blood sample extraction by cardiac puncture. Blood was collected in 
ethylenediaminetetraacetic acid vacutainer tubes for subsequent determination of 
haematological parameters. The tubes were centrifuged at 1,500 x g for 10 min, and the 
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supernatants were removed and stored at -20°C until assayed. Liver and spleen: 
samples were washed with saline solution, weighted and frozen at -20º C until 
lyophilisation. For iron quantification, samples of liver and spleen tissues from 2 birds 
belonging to same diet were pooled and mashed (6 replicates per diet, 2 birds per 
replicate). For AC magnetic susceptibility measurements, pooled samples of liver and 
spleen tissues were prepared from mashed tissues out of 6 replicates with 2 birds per 
replicate. Duodenum: samples from 7 birds per diet were taken and washed with saline 
solution and divided into 3 different fragments. The first portion of duodenum 
intestinal mucosa was cleaned with saline solution before preserving in a clean micro-
centrifugetube (1.5 ml) and stored at -80ºC after freezing in liquid nitrogen for 
posterior gene expression study. The second duodenum portion was directly placed in 
10% formalin 0.1 phosphate buffer (pH = 7) for subsequent histological studies. The 
third duodenal portion was frozen at -20ºC until lyophilisation for iron quantification. 
2.7 Duodenal morphological studies 
Samples were processed for 24 h in a tissue processor with ethanol and were embedded 
in paraffin. Sections (5 µm) were prepared from duodenal tissue and were stained with 
hematoxylin-eosin. Histological sections were examined with an an Olimpus optical 
microscope (Olimpus Optical Co., GmbH, Hamburg,Germany). The images were 
analyzed using an image software (Soft Imaging System, Olimpus, Hamburg, 
Germany). The variables measured were villus height, and crypt depth. A total of 10 
intact, well-oriented villus-crypt units selected for each intestinal cross-section (6 
cross-sections/sample). Villus height (µm) was measured from the tip of the villus to 
the villus-crypt junction, and crypt depth was defined as the depth of the invagination 
between adjacent villi. The average of these values was used for statistical analysis.  
2.8 Iron quantification in faeces, tissues and diets 
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 Cage pooled faeces, liver, spleen and duodenum tissues were lyophilised and mashed 
prior to acid digestion. Samples were incubated with 65% nitric acid (1 ml, 1 h, 60°C) 
for total iron quantification analysis determined per gram of tissue. Quantitative 
determination of iron was analysed by Inductively Coupled Plasma Atomic Emission 
Spectroscopy (Perkin Elmer OPTIMA 2100 DV). 
2.9 Solubility studies 
 The solubility tests was done according to the standardized method of Swain et al. 
[41] considering 30 and 60 min as gizzard transit times, 40ºC[42] as physiological 
temperature and three different pH values (1,2 and 3) to reproduce the acid gastric 
conditions[43] into gizzard of 21
st
 days old birds. The digestion volume was often 
gently shaken to simulate the gizzard peristaltic motion. Quantitative determination of 
iron was analyzed by Inductively Coupled Plasma Atomic Emission Spectroscopy 
(Perkin Elmer OPTIMA 2100 DV). 
2.10 Total RNA Extraction from duodenum tissues 
 Total RNA was extracted from seven duodenal tissue samples per diet by using 
RNeasy Mini Kit (Qiagen, Valencia, CA) and following the manufacturer’s instruction, 
(Animal Tissues and Cells, DNase Digest). The extracted RNA mass values ranges 
from 4 to 29 mg. An automated RNA extraction system (QIAcube system, Qiagen) 
was used, in order to get the highest reproducibility. Total RNA was finally dissolved 
in 30 µL elution buffer and stored at –80° C. The quantity and quality of total RNA 
were assessed on a NanoDrop-ND 1000 (Thermo Fisher Scientific Inc., Boston, MA) 
and an Agilent 2100 Bioanalyzer, respectively. An aliquot of total RNA (1 µL) was 
analyzed in an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA) 
using appropriated RNA Chips and reagents. The RNA integrity number (RIN) value is 
an empirical measure of RNA integrity based on the intensities of 28s and 18s rRNA 
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bands. The RIN value is based on an algorithm that assesses a number of features 
derived from an electropherogram profile for a given sample. 
2.11 DMT1, DcytB, FPN and β2-m Gene Expression Analysis 
cDNA was produced using the GoTaq Two Step RT-PCR System A6010 (Promega, 
Madison, WI, USA) in a total volume of 20 µl, with 536 ng of total RNA, following 
the manufacturer’s protocol. No-template and no-reverse-transcription controls were 
included for each reverse-transcription run for the control treatment. cDNA was stored 
at -20ºC for later use. Polymerase chain reactions for duodenal DMT1, DcytB and FPN 
genes were carried out with primers described previously by Tako et al.[36], while the 
β2-m cDNA was amplified with primers designed by Yu et al.[44]. Amplification 
reactions were performed in a 25 µl volume with 2 µl of cDNA and 250 nM of each 
primer, in iQ5 96-well PCR plates (Bio-Rad). Thermal cycling conditions consisted of 
1 cycle at 95°C for 2 min and 40 cycles of denaturation (15 s) and annealing and 
extension (60 s). After the reaction, a melting curve analysis from 65ºC to 95ºC was 
applied to ensure consistency and specificity of the amplified product. Eukaryotic 18S 
rRNA (Endogenous 18S rRNA, part # 4352930E, Applied Biosystems, Carlsbad, CA, 
USA) was used as endogenous control for relative gene expression quantification. 18S 
sRNA was amplified in a different tube. The data mining and quantification of the gene 
expression levels were determined by the number of cycles needed for the 
amplification to reach a fixed threshold in the exponential phase of the PCR reaction. 
The number of cycles is referred to as the quantification cycle (Cq) value. The level of 
mRNA was normalized to 18S rRNA expression in each sample and presented as the 
∆Cq value (∆Cq = Cq target mRNA– Cq 18S rRNA)[45]. Real Time PCR analysis of 
∆Cq for each sample was performed in triplicate, the average of these three values was 
used for statistical analysis.  
Page 10 of 27CONFIDENTIAL - AUTHOR SUBMITTED MANUSCRIPT  NANO-106253.R1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
11 
 
2.12 Statistical analysis 
Data from the animal assays were subjected to a one-way analysis of variance by using 
the general linear model procedure (version 9.2, SAS Institute Inc., Cary, NC). Data 
are shown as mean values ± standard error of the mean (s.e.m). When the effect was 
declared significant (P<0.05), means were compared using a Tukey's Studentised range 
test. 
3. Results and Discussions 
3.1 Iron oxide nanoparticles  
Single-phase γ-Fe2O3 nanoparticles with AD coating of 12 ± 2 nm size were prepared 
for dietary Fe(III) supplementation. The as-synthesized are highly crystalline 
nanostructures as shown in Figure 1. AD coating provides biocompatible features to 
IONP which have been widely tested in in vitro and in vivo studies[46]. The magnetic 
properties of AD coated IONP are shown in Figure 2. On one hand, the magnetization 
cycles show superparamagnetic features with saturation magnetization values around 
70 A·m
2
/kgγ-Fe2O3 and negligible values of remanent magnetization and coercive field at 
room temperatures. On the other hand, the temperature dependence of the AC 
magnetic susceptibility is a high-sensitive technique for the detection of IONP in 
tissues. The AC magnetic susceptibility has two components: the in-phase 
susceptibility (χ’) and the out-of-phase susceptibility (χ’’). The out-of-phase 
component χ’’(T) is only sensitive to mineralised iron, as the one forming the AD 
coated IONP, while the in-phase component χ’(T) includes the contribution from both 
mineralised iron, paramagnetic iron or other diamagnetic contributions[47]. Figure 2b 
shows the temperature dependence of χ’’of the AD coated IONP powder. Briefly, the 
temperature behaviour of χ’’(T) shows a maximum at around 220 K accompanied by a 
small shoulder at around 40 K. The maximum observed around 220 K is related to 
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magnetic relaxation processes, while the feature observed at 40 K could be related to 
an uncoherent reversal of the magnetic moments of single domain non-interacting 
particles[48]. The overall thermal behaviour of χ’’(T) can be used as an IONP 
fingerprint for tracking its presence in animal tissues or faeces after 14 days of oral 
exposure.  
3.2 Birds and diets  
Growing broiler Cobb chickens were employed in the dietary study. It has been 
recently shown that broiler chickens are a suitable animal model for iron 
bioavailability studies due to similarities with the human gastrointestinal tract[28, 36]. 
The timeline of the experimental procedure, dietary iron dose and sources employed 
are shown in Figure 3. Initially, 60 male broiler Cobb chickens 1-day-old were fed ad 
libitum with ferrous sulphate supplemented diet (diet B) along an adaptation period of 
7 days to warrant an iron sufficient diet avoiding epithelial alteration which may 
influence the results of our dietary study. After the adaptation period, dietary treatment 
period starts. From 8th day to 21
st
 day, the bird weight increases 4-fold from 189 ± 3 g 
to 759 ± 69 g revealing that growing birds need to satisfy strong nutritional 
requirements along the dietary treatment period. In case of γ-Fe2O3 IONP 
supplemented diet (diet C), the accomplishment of iron requirements implies that each 
bird would ingest, in average, a total IONP mass of 58 mg along the dietary treatment 
period. 
 3.3 Animal observation, food consumption, and body weight  
During the period from day 8
th
 to 21
st
, all birds grew in similar way independently of 
diet, achieving a similar appearance and average weight (759 ± 69 g) at the end of 
dietary treatment period. The total fed intake (756 ± 16 g) and weight gain (570 ± 30g) 
were comparable for all diets along 14 days. In case of birds fed on γ-Fe2O3 IONP 
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supplemented diet, the daily IONP dose varies from 24 mg of IONP per kg of bird at 
day 8
th
 to 6 mg/kg at day 21
st
 when considering the average ingested IONP mass (4 
mg) per bird and day and the variation of weight gain along the dietary treatment 
period, Therefore, the study remains in a low IONP dose range (<300 mg/kg) -
according to the dose range established by Kumari et al.[37]- where no toxicological 
effects are expected. Indeed, no adverse signs, symptoms, or mortality were observed 
in birds fed on γ-Fe2O3 IONP supplemented diet. This is reflected on the ratios of fresh 
liver and spleen/ animal weights, comparable for all diets as shown in Figure 4. The 
fact that liver and spleen weights are not influenced by diets implies that no 
toxicological signs such as inflammation were manifested in the animal growth of 
birds fed on IONP supplemented diet after 14 days.  
3.4 IONP biodistribution and excretion  
The IONP organ biodistribution analysis after chronic oral exposure was carried out on 
liver and spleen of birds fed on different diets. Several IONP biodistribution studies in 
animal models showed preferential accumulation in spleen and liver after intravenous 
injections, and to a lesser extent in other organs, depending on dosage[49], surface 
coating[49-50] or intravenous administration methodology[51]. The total IONP intake 
(58 mg) per bird along the dietary treatment period represents a relevant amount of 
magnetic nanomaterial for testing their safety since its accumulation in duodenum, 
spleen and liver can be tracked by AC magnetic measurements. Nonetheless, no signs 
of IONP accumulation in liver and spleen were observed for birds fed on γ-Fe2O3 
IONP supplemented diet as shown in Figure 5. These results prove that after IONP oral 
exposure during 14 days, the accumulated IONP amounts in liver or spleen are 
insignificant or under the detection limit of AC magnetic susceptibility measurements. 
IONP do not achieve blood stream from the gastrointestinal tract spite birds were fed 
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ad libitum during 14 days. However, faecal AC magnetic data from birds fed on IONP 
supplemented diet show a χ’’(T) profile (see Figure 5c) which highly resembles the 
IONP powder data shown in Figure 2b. The slightly different temperature location of 
the χ’’(T) maximum, in comparison with the IONP powder could be probably related 
to either a different IONP aggregation degree[49], partial degradation of IONP, or 
both. In any case, excretion results reveal that IONP are highly ejected along the 
gastrointestinal tract.  
3.5 Influence of dietary IONP treatment on iron storage 
The different iron sources employed in diets may result in distinct iron solubility 
leading to different iron storage and transport pathways. Acid gastric conditions[43] 
and digestive transit times[42] of twenty-one-days-old Broiler chickens were simulated 
by in vitro acid digestions in order to detect and quantify by analytical means the 
release of iron atoms from IONP during their degradation. Table 1 shows the results of 
the iron solubility[52]  from IONP under the different pH and acidic digestion times, 
mimicking gastric digestion conditions. The degradation of γ-Fe2O3 nanoparticle 
releases ferric iron. Solubility values shown in Table 1 are highly low (~2% in the best 
conditions) for all experimental conditions. These results reflect a poor biodegradation 
of IONP into Fe(III) under acid gastric conditions, what may  explain the large amount 
of IONP present in faeces observed in Figure 5c. These experiments confirm the 
intestinal tract as an efficient excretion route. Other relevant information extracted 
from excreta is that faecal iron level is tightly correlated with diets. The faecal iron 
level in birds fed on non-iron supplemented diet shows significantly lower value than 
iron supplemented diets. Since faeces are the main IONP excretion route, we assess their 
accumulation along intestinal tract by checking the duodenal iron level for different diets. 
Thus, we observed that duodenal iron level has similar values in birds fed on non-iron and 
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IONP supplemented diets but these values are significantly lower than for birds fed on 
ferrous sulphate supplemented diet (see Figure 6d). Such similarities for non-iron and γ-
Fe2O3 IONP supplemented diets suggest no IONP accumulation in duodenum. The 
different duodenal iron levels associated with distinct dietary iron sources (i.e. iron 
sulphate or IONP) can be related to their different iron solubility and/or absorption 
mechanisms. Indeed, it is well accepted[53] that Fe(II) has higher solubility than Fe(III) 
leading to higher iron absorption and efflux rates. This is in agreement with the dietary 
effects on the liver iron shown in Figure 6b for Fe(II) from iron sulphate and Fe(III) 
from IONP. Liver iron levels are significantly higher in birds fed on ferrous sulphate 
supplemented diet than in case of non-iron supplemented-one, while IONP 
supplemented diet shows intermediate values. This is an important result which reflects 
that iron from IONP is partially bioavailable. Besides, iron amount detected in spleen is 
similar for all diets (see Figure 6a). Considering that the iron supplement amount (FeSO4 
or γ-Fe2O3  IONP) represents the 40% of the iron amount present in basal diet (i.e. Diet 
A), the effects on liver iron underline that iron supplementation by IONP should be 
considered as physiological. 
Haematological parameters have been also analysed since they are expected to be 
sensitive to iron storage[54]. We have observed no influence of diets on the number of 
red blood cells, and haematocrit, haemoglobin and serum iron concentrations and their 
correspondence to bird age (see Tables S1 and S2 in Supporting Information). 
Similarly, the serum proteinogram does not reflect differences between diets. Hence, 
haematological data reveal normality after 14 days of oral exposure to IONP as 
expected for a low dose (i.e. <24 mg/kg)[37]. 
3.6  Dietary IONP effects on duodenal morphology 
Page 15 of 27 CONFIDENTIAL - AUTHOR SUBMITTED MANUSCRIPT  NANO-106253.R1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
16 
 
Recent works show that the oral exposure to distinct types of nanoparticles may 
influence the activity of the intestinal epithelium. On one hand, iron- and insulin-
containing nanoparticles can be efficiently absorbed acting as efficient iron[55] and 
insulin sources[24]. On the other hand, chronic and acute oral exposure to polystyrene 
carboxylated nanoparticles[28] negatively affects iron absorption at the intestinal 
epithelial layer. In order to assess the expression of any epithelial alteration in birds 
after 14 days of oral exposure to IONP we have analyzed the morphology of intestinal 
villi. In general, we observe no alteration or atrophy of duodenal morphology, contrary 
to recent works[22, 28], which  report alterations in the epithelial intestine of chickens 
after oral exposure to nanoparticles. This can be due to the fact that we use iron 
sufficient birds avoiding histological changes, which may alter the epithelial 
functioning. The villi absorption surface tightly depends on the dietary iron as shown 
in Figure 7 where the villus heights and crypt depths of duodenal tissues are depicted 
for birds subjected to different diets. While villus height and crypt depth of birds fed 
on iron supplemented diets are similar, these values are higher than the one observed 
for the non-iron supplemented diet. Interestingly, these results show that villus 
morphology is highly related to dietary iron level. This is in agreement with recent 
results showing that iron deficiency induces gastrointestinal manifestation such as 
intestinal atrophy whilst non-haematological manifestations are observed[56]. Hence, 
lower values of villus height and crypt depth are associated with non-iron 
supplemented diet where dietary iron reduction is around 30% lower than for iron 
supplemented diets. Furthermore, the intestinal villi development agrees with the liver 
iron levels shown in Figure 6b. As the IONP accumulation in the liver of birds fed on 
IONP supplemented diet has not been observed by AC magnetic measurements, we 
believe that the observed enhancement of liver iron concentration is probably 
associated with biogenic species such as ferritin. The AC magnetic signal from ferritin 
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is 100 times lower than γ-Fe2O3 IONP and its observation requires animals with iron 
overload [57-58], what is not the case in our study. Thus, the higher villi development 
observed for birds fed on iron supplemented diets (independently on the iron source) 
than the non-iron supplemented-one underlines the iron bioavailability from ingested 
IONP. Recent studies[22-23, 35] show that iron absorption from nanosize structures is 
favoured in comparison to microsize or bulk courterparts. Furthermore, authors suggest 
that the luminal non-haem iron released from nanostructures would imply ferrous 
absorption pathways (i.e. DMT1 and DcytB proteins) without showing experimental 
evidences. 
3.7 Dietary IONP effects on duodenal gene expression 
Iron absorption mechanisms are known to depend on iron forms. As mentioned above, it 
is well accepted the high bioavailability of Fe (II) from iron sulphate[35] and its 
absorption mechanism involving Dcytb-DMT1 proteins[30]. Figure 8 shows the results 
of DMT1, DcytB, β2-m and FPN gene expression analysis. At first glance, the 
expression of DcytB and DMT1 shows similar values for non-iron supplemented and 
ferrous sulphate diets but significantly lower than in case of γ-Fe2O3 IONP supplemented 
diet. On the contrary, the β2-m is significantly overexpressed for birds fed on IONP diet 
in comparison to control diets. β2-m which is one of the four proteins involved in the 
non-haem ferric pathway whose gene expression methodology is available for 
chickens[44]. Finally, FPN displays similar values for all diets revealing that the iron 
efflux from enterocyte to blood stream is performed in similar manner independently on 
the ferrous iron content into the cytoplasm related to different diets. Nevertheless, the 
downregulation of DMT1 and DcytB genes for γ-Fe2O3 IONP supplemented diet 
suggests an inhibition of ferrous transport pathways while ferric pathway is increased. 
Such possibility involves mucins, which play an important role to trigger ferric pathways 
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instead of ferrous-ones[32]. This may explain our experimental findings on Fe(III) 
released from the partial transformation of crystalline γ-Fe2O3 nanoparticles under acid 
gastric conditions. Fe(III) is susceptible to bind mucins[59] favoured by the low 
solubility of the ferric form into the intestinal mucosa  resulting in bioavailable iron.  
4. Conclusions 
The influence of oral exposure to γ-Fe2O3 nanoparticles at low concentration in the diet 
during 14 days has been assessed in growing broiler chickens. The ingestion of γ-Fe2O3 
nanoparticles within this growing period has not shown toxicological symptoms on 
growth parameters, intestinal or haematological alterations. Our results show that γ-
Fe2O3 nanoparticles are not accumulated in liver, spleen, or duodenum but mainly 
excreted by faeces. Liver iron level and duodenal villi morphology reveals the 
bioavailability of Fe(III) resulting from a partial transformation of γ-Fe2O3 
nanoparticles under acid gastric environment. Iron absorption mechanisms are assessed 
after oral exposure to iron containing nanoparticles. Duodenal gene expression studies 
related to non-haem iron proteins indicates that ferrous pathways are inhibited while 
ferric pathways are enhanced suggesting the participation of mucins in the iron 
transport into enterocytes. Our findings reveal that oral administration of iron oxide 
nanoparticles is a safe route for drug delivery at low dose. Nanotechnology opens new 
avenues towards nanoparticle engineering for providing customized iron forms and 
fractions, allowing to control iron solubility and absorption rates. 
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Figures and Tables 
 
 
Figure 1. Structural characterization of nanoparticles (A) TEM micrograph of IONP. Scale 
bar:40 nm. Inset: HRTEM micrograph of IONP. Scale bar: 5 nm, (B) size distribution (log 
normal fit) of IONP. 
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Figure 2. Magnetic characterization of nanoparticles (A) Mass-normalized magnetization 
cycle of IONP powder at room temperature, (B) Temperature dependence of χ'' of IONP 
powder. 
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Figure 3. Timeline and experimental design (A) Dietary iron source and dose, (B) Timeline 
of animal feeding and selection schedule, animal groups, diets, selection criteria, and sample 
collection. 
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Figure 4. Influence of diets on fresh organ weight (A) fresh spleen/animal weight ratio 
(n=12), (B) fresh liver/animal weight ratio (n=12). Error bars, ± s.em. 
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Figure 5.  Temperature dependence of χ” in different tissues from birds fed on different diets 
(A) liver tissues, (B) spleen tissues, (C) faeces. In (A,B), pooled samples of liver and spleen 
tissues were prepared from mashed tissues out of 6 replicates with 2 birds per replicate. In 
(C), pooled sample per diet was prepared out of 3 replicates with 4 birds per replicate. 
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Figure 6. Influence of diets on the iron concentration in (A) spleen tissues (n=6 replicates,2 
birds/replicate), (B) liver tissues (n=6 replicates,2 birds/replicate), (C) pen pooled faeces (n=3 
replicates,4 birds/replicate), (D) duodenum tissues (n=7). Error bars, ± s.e.m. In (B-D), 
significant dietary differences (P<0.05) on iron liver, spleen and duodenum average 
concentration values are indicated by contrast characters (a,b) according to a one way analysis 
of variance with Tukey’s post test. 
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Figure 7: Influence of diets on duodenal morphological parameters (A) villus height (n=7), 
(B) crypt depth (n=7). Error bars, ± s.e.m. In (A-B), significant dietary differences (P<0.05) 
on average villus and crypth values are indicated by contrast characters (a,b) according to a 
one way analysis of variance with Tukey’s post test. 
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Figure 8. Influence of diets on mRNA expression of duodenal genes (A) DcytB, (B) 
DMT1,(C) β2-m, (D) FPN. Gene expression levels were determined by real-time quantitative 
reverse-transcription-polymerase chain reaction (n = 7) and expressed relative to 18S rRNA in 
arbitrary units (a.u.).Error bars, ± s.e.m. In (A-C), significant dietary differences (P<0.05) on 
mRNA expression are indicated by contrast characters (a,b) according to a one way analysis 
of variance with Tukey’s post test. 
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Table 1. Solubility of Fe from IONP under different pH and digestion times, mimicking 
gastric digestion conditions. 
 
pH 
Digestion Time  
(min) 
Total Fe mass 
(µg) 
Released Fe mass  
(µg) 
Fe solubility  
(%) 
1 
1 
30 
60 
2770 
3020 
43 
57 
1.6 
1.9 
2 
2 
30 
60 
2560 
2920 
9 
12 
0.3 
0.4 
3 
3 
30 
60 
2550 
2870 
4 
5 
0.2 
0.2 
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